Nucleosomes at Active Promoters: Unforgettable Loss  by Henikoff, Steven
Cancer Cell
Previews
Varambally, S., Dhanasekaran, S.M., Zhou, M., 
Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., 
Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, 
A.P., et al. (2002). Nature 419, 624–629.
Wang, Z., Tseng, C.P., Pong, R.C., Chen, 
H., McConnell, J.D., Navone, N., and 
Hsieh, J.T. (2002). J. Biol. Chem. 277, 
12622–12631.
Yu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., 
Tomlins, S.A., Creighton, C.J., Dhanasekaran, 
S.M., Shen, R., Chen, G., et al (2007). Cancer 
Cell, this issue.Nucleosomes at Active Promoters: 
Unforgettable Loss
Steven Henikoff1,*
1Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
*Correspondence: steveh@fhcrc.org
DOI 10.1016/j.ccr.2007.10.024
A variety of chromatin features have been implicated in the regulation of gene expression, including 
nucleosome occupancy at promoters, histone modifications and variants, and DNA methylation. In 
this issue of Cancer Cell, Lin and colleagues use a powerful single-molecule approach to explore 
the relationship between nucleosome occupancy and gene expression in cancer cells. They show 
that nucleosome occupancy is mostly all-or-none at the multiple start sites of the MLH1 CpG island. 
After demethylation by drug treatment, nucleosomes are permanently lost as transcription becomes 
reactivated. Thus, epigenetic maintenance of gene expression may require that promoters are main-
tained free of nucleosomes.A growing body of evidence has 
revealed that chromatin changes 
correlate with differences in gene 
expression, leading to the widely held 
view that transcription factor binding 
at promoters acts through nucleo-
somes to activate or repress gene 
expression (Li et al., 2007). However, 
it is unclear how the various chroma-
tin differences can lead to changes in 
the on-versus-off state of promoters. 
One idea is that histone modifications 
alter the accessibility of DNA by sta-
bilizing interactions between chroma-
tin-associated proteins and the his-
tones that they bind to (Cosgrove et 
al., 2004). But then how do these his-
tone tail interactions result in up- or 
downregulation of gene expression? 
A paradigm originating from studies 
of the yeast PHO5 promoter is that 
nucleosomes are simply evicted from 
promoters, and the naked DNA that 
results allows for transcription fac-
tors to gain access to their binding 
sites and for the basal transcriptional 
machinery to assemble (Boeger et 
al., 2003; Reinke and Horz, 2003). Indeed, a distinguishing feature of 
active promoters in general is that 
they are depleted in nucleosomes 
relative to silent promoters (Mito et 
al., 2005).
A limitation of studies that have 
been used to map chromatin char-
acteristics, such as histone modi-
fications and variants, is that they 
provide data that are averaged from 
large numbers of individual DNA mol-
ecules. For example, ChIP-chip and 
real-time PCR assays can provide 
sensitive measurements of chromatin 
features and of nucleosome occu-
pancy, but these are relative mea-
surements that cannot distinguish 
between a change in the amount of 
a feature relative to a control and its 
absolute abundance (van Leeuwen 
and van Steensel, 2005). Therefore, 
it has remained possible that the 
reduction in nucleosome occupancy 
seen in such studies is not com-
plete eviction of nucleosomes, but 
rather partial loss or even transient 
unwrapping. To address this uncer-
tainty, Peter Jones’ group introduced Cancer Cell 12, Na single-molecule modification of the 
DNA methylation mapping technique 
for mapping chromatin accessibil-
ity (Fatemi et al., 2005; Kladde et al., 
1996) (Figure 1A). The M.SssI DNA 
methyltransferase specifically meth-
ylates the cytosines of CG dinucleo-
tide base pairs, making these bases 
resistant to deamination by treatment 
with sodium bisulfite. As a result, 
M.SssI methylation of nuclei followed 
by DNA extraction and bisulfite treat-
ment results in DNA with CGs intact, 
but with all other cytosines converted 
to uracil. The uracil bases are repli-
cated as if they were thymines, so 
that PCR amplification, cloning, and 
sequencing of a region using M.SssI- 
and bisulfite-treated DNA yields 
sequences from single molecules in 
which CGs that have been methyl-
ated by M.SssI are sequenced as 
CGs, but those that have escaped 
M.SssI methylation are sequenced 
as TGs. In this way, blocking of a CG 
from the action of M.SssI in nuclei 
can be quantified by sequencing a 
collection of PCR-generated clones, ovember 2007 ©2007 Elsevier Inc. 407
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DNA has been widely used to map 
sites of natural DNA methylation. 
Because nucleosomes will block 
M.SssI from the ~150 bp wrapped 
around the core particle, treat-
ment of nuclei with M.SssI results 
in a high-resolution nucleosome 
occupancy map.
In this issue of Cancer Cell, Lin 
and colleagues (Lin et al., 2007) 
apply single-molecule nucleosome 
occupancy mapping to the MLH1 
“CpG island” that encompasses 
the bidirectional promoter for 
the EPM2AIP1 and MLH1 genes. 
MLH1, which encodes a DNA mis-
match repair protein, has been 
shown to be hypermethylated and 
silenced at the CpG island pres-
ent within its promoter region in a 
variety of cancers. The EPM2AIP1/
MLH1 promoter is bidirectional, 
and MLH1 mRNA is transcribed 
from two nearby start sites. These 
three closely spaced transcrip-
tional start sites (TSSs) span a 630 
bp region that is sufficiently large to 
encompass multiple nucleosomes. 
In normal cells, all three genes are 
active, and traditional nucleosome 
mapping methods show that posi-
tioned nucleosomes lie immediately 
downstream of all three TSSs, but 
the TSSs themselves display low 
nucleosome occupancy. Single-
molecule nucleosome occupancy 
mapping reveals that these TSSs 
are free of nucleosomes in the 
large majority of cases, because 
these cloned sequences have few 
if any unmethylated CGs, and the 
few exceptions show contiguous 
stretches of unmethylated CGs, 
consistent with full nucleosome pro-
tection (Figure 1B). Although limited 
stretches of consistent protection 
from M.SssI are seen at two positions 
in the otherwise accessible regions, 
protection is too short to be caused by 
nucleosomes, but rather suggests the 
presence of tightly bound DNA-bind-
ing proteins. Histones are known to 
be acetylated at active promoters, but 
the absence of nucleosomes at active 
TSSs means that acetylation occurs 
on adjacent nucleosomes, and indeed 
this is what was observed.
The MLH1 promoter provides a suit-
able test case to ask what happens to 
nucleosome occupancy when genes 
are silenced in cancer and reacti-
vated by drug treatment, because the 
genes are activated when 5-aza-CdR, 
a DNA methyltransferase inhibitor, is 
added. This test is complicated by 
the fact that silenced promoters are 
heavily CG methylated, and inhibition 
of endogenous DNA methyltransfer-
ases causes demethylation that can 
be mistaken for a nucleosome occu-
pancy change. To avoid this problem, 
Lin et al. focused on cells that 
had been treated long enough to 
demethylate a substantial frac-
tion of molecules and used PCR 
primers designed to selectively 
amplify only bisulfite-converted 
DNA in which CGs were replaced 
with UGs. The results were clear: 
72 hr after drug treatment, about 
half of the promoter molecules were 
found to be bound by nucleosomes 
essentially throughout the promoter 
region, and most of remainder were 
completely free of nucleosomes at 
the three TSSs. By 44 days fol-
lowing drug treatment, the large 
majority of promoter molecules 
were nucleosome free at these 
sites. The fact that the fraction of 
promoter molecules with nucleo-
some-free regions corresponded 
to the level of gene expression 
in cells treated for 72 hr and 44 
days strongly suggests that TSSs 
bound by nucleosomes are silent 
and those free of nucleosomes 
are active. Moreover, the fact that 
many of the demethylated pro-
moter molecules were still bound 
by nucleosomes 72 hr after drug 
treatment suggests that DNA 
methylation is not directly respon-
sible for reactivation, but rather 
leads to destabilization of pro-
moter nucleosomes, whose loss 
results in reactivation.
Thus, as for the yeast PHO5 
promoter, which is activated by 
eviction of nucleosomes, a gene 
silenced in cancer and reactivated 
by drug treatment also appears 
to be regulated by nucleosome 
occupancy. Studies in a variety of 
model systems have delineated 
the multiple factors that can influence 
the stability of a nucleosome and 
therefore its propensity to be evicted 
from promoters. These include ATP-
dependent remodeling complexes 
that likely provide the driving force 
for eviction, and histone chaperones, 
such as Asf1 (Anti-silencing function 
1), which is involved in both assem-
bly and disassembly of nucleosomes 
(Li et al., 2007). In addition to these 
direct effectors, many other factors 
can alter nucleosome stability, such 
as histone modifications of many 
Figure 1. Single-Molecule Mapping of Nucleo-
some Occupancy
(A) Schematic diagram of the single-molecule meth-
ylation mapping method (Fatemi et al., 2005). M.SssI 
methylates cytosines of CG dinucleotides (blue lolli-
pops) but is blocked by nucleosomes. After bisulfite 
treatment converts unmethylated cytosines to uracils 
(purple U’s), the first round of PCR amplification puts 
in adenine across from uracil, converting a C/G base 
pair to a T/A base pair. Sequencing inserts from a few 
dozen clones identifies C→T changes as unmethyl-
ated cytosines, whereas cytosines are identified as 5-
methylcytosine in the original DNA because they were 
not converted to uracils by bisulfite treatment.
(B) Transcriptional start sites at the bidirectional pro-
moter within the MLH1 CpG island (encoding EP-
M2AIP1, MLH1 1a, and MLH1 1b) are mostly nucleo-
some free when the genes are expressed, and adjacent 
nucleosomes are acetylated (magenta flags) (Lin et al., 
2007). However, when the promoter is silenced in can-
cer, these sites are occupied by nucleosomes (green 
disks). Treatment with 5-aza-CdR results in nucleo-
some eviction and gene reactivation.408 Cancer Cell 12, November 2007 ©2007 Elsevier Inc.
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Previewsvarieties (Cosgrove et al., 2004), the 
histone variants H3.3 and H2A.Z (Jin 
and Felsenfeld, 2007), and chroma-
tin-associated proteins that bind to 
modified histones or to methylated 
DNA (Li et al., 2007). These effec-
tors of nucleosome stability have 
often been referred to as “marks,” 
leaving open the question of how 
marking can result in gene activa-
tion or repression and epigenetic 
maintenance of these states. But if 
these diverse chromatin modifiers 
act by simply increasing or decreas-
ing nucleosome stability, then we Ductal carcinoma in situ (DCIS) is a 
heterogeneous disease, diagnosed 
with increasing frequency since the 
introduction of the mammographic 
screening program (Hofvind et al., 
2007). A number of classification sys-
tems have been proposed, primarily 
based on nuclear morphology. The 
type of DCIS, lesion size, and most 
importantly, distance to excision 
margin have been shown to be strong 
predictors of recurrence (MacDonald 
et al., 2005). Approximately half of 
recurrences remain in situ, while half 
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will be invasive. Patients with invasive 
carcinoma are at risk of metastases, 
and hence this represents a signifi-
cant event for the patient.
Several studies have demonstrated 
that the risk of in situ and invasive 
recurrence is greater for high-grade 
compared to low-grade DCIS. This 
would suggest that more aggressive 
therapy is indicated for high-grade 
lesions, and although the best treat-
ment for DCIS is still uncertain, there 
is little doubt that a margin ≥10 mm, 
endocrine therapy, and radiotherapy 
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following excision reduces the risk of 
recurrence (MacDonald et al., 2005; 
Burstein et al.,2004). Nonetheless, it 
is clear that our ability to accurately 
predict which patient will recur is 
limited, leading to under- or over-
treatment.
In the current issue of Cancer Cell, 
Gauthier et al. (2007) suggest that a 
simple panel of markers may solve 
that problem. DCIS with high P16+ 
and/or COX2+ and high Ki67+ con-
fers a significant risk of subsequent 
in situ and invasive recurrence. What 
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ton QLD 4006, Australia
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